HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Low LDL cholesterol, albuminuria, and statins for the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry.

AbstractOBJECTIVE:
LDL cholesterol <2.80 mmol/l was associated with increased cancer risk in type 2 diabetes. We explored the 1) interaction between low LDL cholesterol and albuminuria and 2) interaction between copresence of these two risk factors and statin use for cancer in type 2 diabetes.
RESEARCH DESIGN AND METHODS:
We analyzed prospective data for 3,793 Chinese type 2 diabetic patients who remained naive for statin treatment and 1,483 patients in whom statin treatment was initiated during a median follow-up period of 5.24 years. All patients were free of cancer at baseline. Biological interactions were estimated using relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S). RERI > 0, AP > 0, or S > 1 indicates biological interaction.
RESULTS:
In 3,793 statin-naive type 2 diabetic patients, copresence of low LDL cholesterol and albuminuria increased cancer risk by 2.8-fold (hazard ratio 2.77 [95% CI 1.78-4.31]) with significant biological interactions (RERI 1.05 [0.04-2.06]; AP 0.38 [0.09-0.66]). In the whole cohort of 5,276 type 2 diabetic patients, there was interaction between nonuse of statins and copresence of low LDL cholesterol and albuminuria with increased cancer risk (RERI 2.87 [0.64-5.09] and AP 0.60 [0.29-0.90]). Statin nonusers with LDL cholesterol <2.80 mmol/l and albumunuria had a 4.9-fold risk of cancer compared with statin users with or without both risk factors.
CONCLUSIONS:
In type 2 diabetes, there was interaction between low LDL cholesterol and albuminuria with increased cancer risks. The latter was attenuated in the presence of statin treatment.
AuthorsXilin Yang, Wing Yee So, Ronald C W Ma, Gary T C Ko, Alice P S Kong, Hailu Zhao, Andrea O Y Luk, Christopher W K Lam, Chung Shun Ho, Peter C Y Tong, Juliana C N Chan
JournalDiabetes care (Diabetes Care) Vol. 32 Issue 10 Pg. 1826-32 (Oct 2009) ISSN: 1935-5548 [Electronic] United States
PMID19592629 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
Topics
  • Adult
  • Aged
  • Albuminuria (physiopathology)
  • Cholesterol, LDL (blood)
  • Diabetes Mellitus, Type 2 (complications, drug therapy)
  • Female
  • Hong Kong
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
  • Male
  • Middle Aged
  • Neoplasms (epidemiology, etiology)
  • Registries
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: